Paros IBio's 'Lasmotinib' preclinical results published in research journal
Predicted impact: Low· Actual: −3.0% vs sector, volume 0.8× normal (5 trading days)
Preclinical research publication; no financial size or regulatory milestone disclosed.
Pharos iBio파로스아이바이오
388870 · KOSDAQ · ₩388870 · 파로스아이바이오
₩5,810▼ ₩30 (0.51%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y +18.94%
- Market cap
- ₩75B
- Enterprise value
- ₩78B
- P/E
- —
- P/B
- 7.7×
- Dividend yield
- 0.0%
- ROE
- −96.0%
- Net margin
- —
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−52.1% from the high
₩3,710Today: ₩5,740 – ₩6,150₩12,120
Returns
- 1W−5.8%
- 1M+5.6%
- 3M+23.2%
- 6M−37.9%
- YTD−38.1%
- 1Y+18.9%
- Volume today
- 20,500
- 0.3× the 20-day average
- Traded today
- ₩120M
- Listed shares
- 12,945,932
- EPS (12 months)
- −₩720
- Earnings yield −12.4%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 29 of 100 (50 is a normal day for this stock).
- MomentumFlat6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Pharos iBio stock overview
Pharos iBio (파로스아이바이오, KRX: 388870) is listed on KOSDAQ, in the Biotech & Pharma sector. Phiverse is a Korean R&D company developing innovative drugs for rare and hard-to-treat diseases, especially cancer, using its AI-based drug discovery platform called Chemiverse, which combines large-scale compound big data with multi-omics analysis to support work from target discovery through preclinical candidate selection. Its shares closed at ₩5,810 on Oct 27, 2026, down 0.51% on the day, giving it a market value of ₩75B.
Key facts
- Market cap
- ₩75B
- Sector
- Biotech & Pharma
- Latest price change
- −0.51%
- As of
- Oct 27, 2026
- Main business
- Phiverse is a Korean R&D company developing innovative drugs for rare and hard-to-treat diseases, especially cancer, using its AI-based drug discovery platform called Chemiverse, which combines large-scale compound big data with multi-omics analysis to support work from target discovery through preclinical candidate selection.
Quick answers about Pharos iBio
- What does Pharos iBio do?
- Phiverse is a Korean R&D company developing innovative drugs for rare and hard-to-treat diseases, especially cancer, using its AI-based drug discovery platform called Chemiverse, which combines large-scale compound big data with multi-omics analysis to support work from target discovery through preclinical candidate selection. Its business model centers on bringing rare disease treatments to conditional approval after Phase 2 trials and generating revenue by licensing drug candidates, and it does not manufacture or sell finished drugs. Its lead pipeline includes lasmotinib (PHI-101) for acute myeloid leukemia, PHI-101-OC for recurrent ovarian cancer, and PHI-501 for solid tumors such as melanoma and colorectal cancer.
- What is the market cap of Pharos iBio?
- The market capitalisation of Pharos iBio was ₩75B at the close on Oct 27, 2026.
- Who are the largest shareholders of Pharos iBio?
- According to the latest official filings, the largest reported holders are Yoon Jung-hyuk (21.43%, as of Jun 4, 2026); Company K (6.25%, as of Jan 9, 2026); Kim Kyu-tae (0.39%, as of Jul 21, 2025).
- When is the next earnings report from Pharos iBio?
- Korean companies rarely announce results dates in advance. Based on when Pharos iBio filed the same report in past years, its next 3q results is expected between Nov 11, 2026 and Nov 14, 2026.
Company profile
Phiverse is a Korean R&D company developing innovative drugs for rare and hard-to-treat diseases, especially cancer, using its AI-based drug discovery platform called Chemiverse, which combines large-scale compound big data with multi-omics analysis to support work from target discovery through preclinical candidate selection. Its business model centers on bringing rare disease treatments to conditional approval after Phase 2 trials and generating revenue by licensing drug candidates, and it does not manufacture or sell finished drugs. Its lead pipeline includes lasmotinib (PHI-101) for acute myeloid leukemia, PHI-101-OC for recurrent ovarian cancer, and PHI-501 for solid tumors such as melanoma and colorectal cancer.
Written by AI from the company's latest annual report.
- Korean name
- 파로스아이바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 윤정혁
- Founded
- Apr 2016
- Listed
- Jul 2023
- Listed shares
- 12,945,932
- Fiscal year ends
- Month 12
- Website
- www.pharosibio.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- Half-year report (Jun 2026)Aug 13, 2026
- Adjustment of Conversion Price (1st Series)Jul 20, 2026
- Insider shareholding reportJun 4, 2026
- Other management mattersJun 1, 2026
- Quarterly report (Mar 2026)May 14, 2026
Titles in Korean until English translations are added.
Also known as: Pharos iBio / 파로스아이바이오 / 388870 / KRX:388870
Source: KRX statistical information